[THE INVESTOR] On Oct. 20, Whanin Pharmaceuticals (016580) fell 0.65% to 15,400 won (US$13.73). It had declined 4.38% through the past month. Standard deviation, which indicates volatility of stock, records 1.7% on the same period over one month.

Compared with its close competitors within the same industry, KOSPI, even though the monthly earnings rate of Whanin Pharmaceuticals was negative, its volatility for 1 month was lower than that of its peer group's. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -2.5%. With low volatility, the return-on-risk remained around the average of its peer group. However, compared with the KOSPI industry, the return-on-risk is below the industrial mean, 1.0, and thus it is hard to say that the industrial comparison performance was positive.

From Oct. 17, institutions have been continuously selling Whanin Pharmaceuticals during the past 3 trading days. As a shareholding sum by investor group for the past 4 weeks, foreigners have sold 98,721 shares with maintenance of a selling position and institutions have sold 1,947 shares with a changing stance to selling from buying. However, during the same period, individuals have bought 100,668 shares with an increasing position.

Cumulated shareholdings per investor group (1Mo) Total shareholdings per investor group

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.